This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

5 Biotech Stocks Under $5 Blasting Off

Stocks in this article: BPAX BMTI ABIO GERN PATH

BioMimetic Therapeutics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

BioMimetic Therapeutics (BMTI) is a biotechnology company. BioMimetic Therapeutics is engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. This stock is trading up 8.3% to $3.77 in recent trading.

Today's Range: $3.45-$3.78

52-Week Range: $1.87-$4.20

Volume: 178,000

Three-Month Average Volume: 219,025

>>5 Stocks With Big Insider Buying

From a technical perspective, BMTI is soaring higher here with decent volume, and this move has pushed the stock above some near-term overhead resistance levels at $3.44 to $3.68. Traders should now look to play the next major breakout for BMTI. That trade will trigger once BMTI takes out some near-term overhead resistance at $3.78 with high volume.

Traders should look for long-biased trades if BMTI can sustain a move or close above $3.78 with volume that's near or above 219,025 shares. If that breakout triggers soon, then look for BMTI to re-test and possibly take out its next major overhead resistance level at $4.20. If that $4.20 level gets taken out with volume, then BMTI could be on its way to $5 in the near future.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,251.87 -164.98 -0.95%
S&P 500 2,006.07 -15.18 -0.75%
NASDAQ 4,658.6880 -24.7190 -0.53%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs